Evox Therapeutics
An exosome therapeutics company founded in 2016 and based in Oxford, UK, that uses exosomes to deliver small and large molecule therapeutics. The company has a proprietary technology to modify exosomes to target specific organs such as the brain and central nervous system.
All edits
March 22, 2019
On March 22, 2019 Evox Therapeutics was awarded a grant from Innovative UK worth £1.5 million.
November 18, 2018
On November 13, 2018 Evox therapeutics was awarded in grant from Duchenne UK worth £655 thousand.
September 2, 2018
On September 2, 2018 Evox Therapeutics completed their series B funding round with £35 in funding from Redmile Group (lead investor), Panacea Venture, Oxford University Innovation, Oxford Sciences Innovation, GV, Cowen Healthcare Investments, and Borealis Ventures.
May 16, 2016
On May 16, 2016 Evox Therapeutics completed their series A funding round with £10 in funding from Oxford Sciences Innovation.
On May 16, 2016 Evox Therapeutics completed their series A funding round with £10m in funding from Oxford Sciences Innovation.
On September 2, 2018 Evox Therapeutics completed their series B funding round with £35m in funding from Redmile Group (lead investor), Panacea Venture, Oxford University Innovation, Oxford Sciences Innovation, GV, Cowen Healthcare Investments, and Borealis Ventures.
On November 13, 2018 Evox therapeutics was awarded in grant from Duchenne UK worth £655k .
On March 22, 2019 Evox Therapeutics was awarded a grant from Innovative UK worth £1.5 million.
Evox Therapeutics is a biotechnology company developing exosome therapeutics using exosomes, cell-derived vesicles, to deliver small and large molecule therapeutics. The company is headquartered in Oxford, Oxfordshire, United Kingdom and was founded in 2016 by Per LundinPer Lundin.
Find more companies like Evox Therapeutics
